CymitQuimica logo
Angiogénese

Angiogénese

Os inibidores da angiogênese são compostos que interferem na formação de novos vasos sanguíneos, um processo crítico no crescimento e metástase do câncer. Ao inibir a angiogênese, esses compostos podem restringir o suprimento de sangue para os tumores, retardando ou interrompendo seu crescimento. Os inibidores da angiogênese são essenciais na pesquisa do câncer e no desenvolvimento terapêutico, fornecendo insights sobre os mecanismos de progressão tumoral e oferecendo potenciais tratamentos para o câncer e outras doenças relacionadas à angiogênese. Na CymitQuimica, oferecemos uma ampla gama de inibidores da angiogênese de alta qualidade para apoiar sua pesquisa em oncologia e biologia vascular.

Subcategorias de "Angiogénese"

Exibir 6 mais subcategorias

Foram encontrados 2243 produtos de "Angiogénese"

Ordenar por

Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
produtos por página.
  • PROTAC EGFR degrader 3

    CAS:
    Potent PROTAC EGFR degrader 3; excellent against H1975/HCC827 cells; lysosome-involved mutant degradation.
    Fórmula:C60H77N13O5S
    Cor e Forma:Solid
    Peso molecular:1092.4

    Ref: TM-T74351

    5mg
    A consultar
    50mg
    A consultar
  • JAK-IN-15

    CAS:
    JAK-IN-15 is a JAK inhibitor. WO2016119700A1 (Compound 15).
    Fórmula:C22H23FN4O3S
    Cor e Forma:Solid
    Peso molecular:442.51

    Ref: TM-T39400

    5mg
    873,00€
  • SJF 1521

    CAS:
    SJF 1521 is an EGFR degrader belonging to the PROTAC class that selectively degrades EGFR while preserving HER2.
    Fórmula:C57H61ClFN7O9S
    Pureza:99.20%
    Cor e Forma:Solid
    Peso molecular:1074.65

    Ref: TM-T36244

    1mg
    449,00€
  • JAK 3 inhibitor IV

    CAS:
    JAK 3 inhibitor IV (ZM 39923 hydrochloride) is a JAK1/3 inhibitor with pIC50 of 4.4/7.1, almost no activity to JAK2 and modestly potent to EGFR; also found to
    Fórmula:C16H19NO
    Pureza:98%
    Cor e Forma:Solid
    Peso molecular:241.33

    Ref: TM-T2460

    25mg
    A consultar
    50mg
    A consultar
    100mg
    A consultar
  • MS39N

    CAS:

    MS39N (compound 27) serves as the negative control for MS39, capable of binding to EGFR without causing its degradation.

    Fórmula:C55H71ClFN9O7S
    Peso molecular:1056.73

    Ref: TM-T208656

    10mg
    A consultar
    50mg
    A consultar
  • FDU73


    FDU73 is a potent and selective BTK PROTAC degrader with a DC50 of 2.9 nM in JeKo-1 cells. It inhibits tumor cell proliferation and exhibits antitumor activity.

    Cor e Forma:Odour Solid

    Ref: TM-T206226

    10mg
    A consultar
    50mg
    A consultar
  • Cetuximab MMAE


    Cetuximab-MMAE, an antibody-drug conjugate (ADC), combines an EGFR-targeting antibody with Monomethyl auristatin E (MMAE) to investigate colorectal and head and neck cancers.
    Cor e Forma:Liquid
    Peso molecular:150 kDa

    Ref: TM-T9901A-219

    1mg
    A consultar
    5mg
    A consultar
  • U3-1784


    U3-1784 is a humanized monoclonal antibody targeting CD334, with anti-cancer activity, used in liver cancer research.
    Cor e Forma:Liquid
    Peso molecular:143.22 kDa

    Ref: TM-T77453

    1mg
    203,00€
    5mg
    604,00€
    10mg
    971,00€
    25mg
    1.438,00€
    50mg
    1.882,00€
  • SNIPER(ABL)-024

    CAS:
    SNIPER(ABL)-024, a compound that conjugates GNF5 (ABL inhibitor) to an LCL161 derivative (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels,
    Fórmula:C52H61F3N8O9S
    Pureza:98%
    Cor e Forma:Solid
    Peso molecular:1031.15

    Ref: TM-T18688

    100mg
    A consultar
    500mg
    A consultar
  • Petosemtamab (FUT8-KO)


    Petosemtamab (FUT8-KO) is a variant of Petosemtamab with the fucosyltransferase 8 gene (FUT8) knocked out. Petosemtamab is a monoclonal antibody (mAb) targeting EGFR (with a Kd of 0.22 nM) and LGR5 (with a Kd of 0.86 nM). This antibody disrupts EGFR signaling and causes receptor degradation in LGR5+ cancer cells. It is applicable in research on solid tumors such as head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (CRC).
    Cor e Forma:Odour Liquid

    Ref: TM-T9901A-486

    1mg
    A consultar
    5mg
    A consultar
  • EGFR/VEGFR2-IN-1


    EGFR/VEGFR2-IN-1 (Compound 10e) serves as an inhibitor for VEGFR-2 and EGFR, with respective IC50 values of 0.26 and 0.14 μM. It inhibits microtubule protein polymerization with an IC50 of 40.9 μM and induces cell apoptosis (Apoptosis). EGFR/VEGFR2-IN-1 is applicable in research related to anti-leukemia and anti-lymphoma treatments.
    Cor e Forma:Odour Solid

    Ref: TM-T200716

    10mg
    A consultar
    50mg
    A consultar
  • ALK-IN-29


    ALK-IN-29 (compound 4c) exhibits inhibitory effects on tyrosine protein kinases such as ALK, CDK2/CyclinE1, and FAK, with the strongest inhibition observed against ALK kinase, displaying a 40.63% inhibition rate at a concentration of 10 μM. ALK-IN-29 is applicable in cancer research.
    Fórmula:C29H32FN3O
    Cor e Forma:Solid
    Peso molecular:457.58

    Ref: TM-T201303

    10mg
    A consultar
    50mg
    A consultar
  • Self-assembling peptide pY1


    Self-assembling peptide pY1, which aggregates around cancer cells, specifically targets the EGFR receptor. When co-cultured with Ovalbumin (OVA), pY1 effectively inhibits the endocytosis of OVA.
    Fórmula:C104H125N24O29P
    Cor e Forma:Solid
    Peso molecular:2206.22

    Ref: TM-TP2934

    10mg
    A consultar
    50mg
    A consultar
  • Anticancer agent 133


    Compound Rh2 (Anticancer agent 133) is a cytotoxic and antimetastatic agent that induces cell cycle arrest, apoptosis, and autophagy.
    Fórmula:C24H19Cl3N5ORh
    Pureza:98%
    Cor e Forma:Solid
    Peso molecular:602.71

    Ref: TM-T78743

    5mg
    A consultar
    50mg
    A consultar
  • EGFR-IN-43


    EGFR-IN-43 (17c) is a potent EGFR inhibitor with ER antagonist action, tamoxifen/endoxifen+gefitinib linkage, and strong anticancer activity.
    Fórmula:C50H55ClFN5O5
    Cor e Forma:Solid
    Peso molecular:860.45

    Ref: TM-T74458

    5mg
    A consultar
    50mg
    A consultar
  • FLT3 Ligand-Linker Conjugate 1

    CAS:
    FLT3 Ligand-Linker Conjugate 1 consists of an FLT3 ligand and a PROTAC linker that can recruit E3 ligase VHL. This conjugate is useful for synthesizing PROTAC RSS0680, a bifunctional compound designed for targeted protein degradation of kinases.
    Fórmula:C29H34N6O4S2
    Cor e Forma:Solid
    Peso molecular:594.748

    Ref: TM-T204140

    10mg
    A consultar
    50mg
    A consultar
  • Os30


    Os30 is a potent fourth-generation EGFR inhibitor, specifically targeting the EGFRC797S-TK mutation with IC50 values of 18 nM for EGFRDel19/T790M/C797S TK and

    Pureza:98%
    Cor e Forma:Odour Solid

    Ref: TM-T81596

    5mg
    A consultar
    50mg
    A consultar
  • Zenocutuzumab

    CAS:
    Zenocutuzumab (MCLA-128) is a humanized antibody targeting HER2, used for research on tumors driven by NRG1 gene rearrangement.
    Pureza:97%
    Cor e Forma:Liquid
    Peso molecular:145.76 kDa

    Ref: TM-T76948

    1mg
    408,00€
    5mg
    1.205,00€
    10mg
    1.843,00€
    25mg
    2.774,00€
  • BCR-ABL-IN-3

    CAS:
    BCR-ABL-IN-3 irreversibly inhibits Bcr-Abl with <100 nM IC50, showing significant anti-cancer effects.
    Fórmula:C20H17ClF2N4O3S
    Cor e Forma:Solid
    Peso molecular:466.89

    Ref: TM-T39732

    5mg
    873,00€
  • FLT3-IN-29


    FLT3-IN-29 (Compound MY-10) is an FLT3 inhibitor with IC50 values of 6.5 nM and 10.3 nM for FLT3-ITD and FLT3-D835Y mutants, respectively. It induces cell cycle arrest at the G0/G1 phase and effectively triggers apoptosis (Apoptosis). Additionally, FLT3-IN-29 reduces reactive oxygen species (ROS) and mitochondrial membrane potential (MMP), displaying anti-leukemic properties.
    Fórmula:C25H30N6O2
    Cor e Forma:Solid
    Peso molecular:446.545

    Ref: TM-T204337

    10mg
    A consultar
    50mg
    A consultar